Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?
2016 · European Journal of Surgical Oncology · 138 citations
https://doi.org/10.1016/j.ejso.2016.06.398
A
Alessandro Bittoni
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(IT)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
174
Papers
2.2K
Citations
27
h-index
54
i10-index
Alessandro Bittoni is an academic researcher from Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Gastric Cancer Management and Outcomes & Pancreatic and Hepatic Oncology Research. The author has an h-index of 27, co-authored 148 publications.
ORCID: 0000-0002-4056-0067Papers by this author
worksTremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
2024 · Annals of Oncology · 60 citations
https://doi.org/10.1016/j.annonc.2024.11.016
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
2021 · Current Treatment Options in Oncology · 50 citations
https://doi.org/10.1007/s11864-021-00870-z
The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey
2014 · Expert Opinion on Investigational Drugs · 36 citations
https://doi.org/10.1517/13543784.2014.912631
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
2024 · The Lancet Oncology · 21 citations
https://doi.org/10.1016/s1470-2045(24)00580-1
Patient-reported outcomes with paclitaxel and ramucirumab switch maintenance in advanced gastroesophageal cancer: A secondary endpoint of the ARMANI phase 3 trial
2025 · European Journal of Cancer · 0 citations
https://doi.org/10.1016/j.ejca.2025.116060
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat